HUP0300998A2 - Karbociklusos oldalláncot tartalmazó metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents

Karbociklusos oldalláncot tartalmazó metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk

Info

Publication number
HUP0300998A2
HUP0300998A2 HU0300998A HUP0300998A HUP0300998A2 HU P0300998 A2 HUP0300998 A2 HU P0300998A2 HU 0300998 A HU0300998 A HU 0300998A HU P0300998 A HUP0300998 A HU P0300998A HU P0300998 A2 HUP0300998 A2 HU P0300998A2
Authority
HU
Hungary
Prior art keywords
group
aliphatic
aromatic
pharmaceutical compositions
side chain
Prior art date
Application number
HU0300998A
Other languages
English (en)
Inventor
Neil Gregory Almstead
Roger Gunnard Bookland
Biswanath De
Matthew J. Laufersweiler
Michael George Natchus
Stanislav Pikul
Joshua S. Tullis
Original Assignee
The Procter & Gamble Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Co. filed Critical The Procter & Gamble Co.
Publication of HUP0300998A2 publication Critical patent/HUP0300998A2/hu
Publication of HUP0300998A3 publication Critical patent/HUP0300998A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D265/10—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A találmány tárgyát az általános képletű metalloproteáz inhibitorvegyületek - ahol R1 hidroxi-vagy hidroxi-amino-csoport; R2hidrogénatom, alifás, aromás, heterociklusos szénhidrogéncsoport; n =0-4; A monociklusos cikloalkilcsoport; E és E' alifás, aromás,heterociklusos szénhidrogéncsoport; L és L' hidrogénatom, alifás,aromás, heterociklusos szénhidrogéncsoport; G kénatom, oxigénatom, -N(R6)-, -C(R6)=C(R6')-, -N=C(R6)- általános képletű csoport ésazocsoport; Z cikloalkil- és heterociklusos alkilcsoport - és optikaiizomereik, diasztereomereik vagy enantiomereik vagy gyógyászatilagelfogadható sóik vagy biológiailag hidrolizálható amidjaik, észtereikvagy imidjeik, valamint alkalmazásuk és ezeket tartalmazógyógyszerkészítmények képezik. Ó
HU0300998A 2000-03-21 2001-03-20 Carbocyclic side chain containing metalloprotease inhibitors, pharmaceutical compositions containing them and their use HUP0300998A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19105900P 2000-03-21 2000-03-21
PCT/US2001/008784 WO2001070682A2 (en) 2000-03-21 2001-03-20 Carbocyclic side chain containing metalloprotease inhibitors

Publications (2)

Publication Number Publication Date
HUP0300998A2 true HUP0300998A2 (hu) 2003-07-28
HUP0300998A3 HUP0300998A3 (en) 2004-10-28

Family

ID=22703974

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300998A HUP0300998A3 (en) 2000-03-21 2001-03-20 Carbocyclic side chain containing metalloprotease inhibitors, pharmaceutical compositions containing them and their use

Country Status (21)

Country Link
US (1) US20030162778A1 (hu)
EP (1) EP1265887A2 (hu)
JP (1) JP2003528078A (hu)
KR (1) KR20030005229A (hu)
CN (1) CN1418209A (hu)
AR (1) AR030196A1 (hu)
AU (1) AU2001249269A1 (hu)
BR (1) BR0109354A (hu)
CA (1) CA2403778A1 (hu)
CZ (1) CZ20023179A3 (hu)
HU (1) HUP0300998A3 (hu)
IL (1) IL151126A0 (hu)
MA (1) MA25783A1 (hu)
MX (1) MXPA02009310A (hu)
NO (1) NO20024482D0 (hu)
PE (1) PE20011187A1 (hu)
PL (1) PL357275A1 (hu)
RU (1) RU2002128003A (hu)
SK (1) SK13362002A3 (hu)
WO (1) WO2001070682A2 (hu)
ZA (1) ZA200206299B (hu)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743587A (en) * 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US4771038A (en) * 1986-01-21 1988-09-13 Ici Americas Inc. Hydroxamic acids
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
ZW23187A1 (en) * 1986-12-15 1988-06-29 Hoffmann La Roche Phosphinic acid derivatives
US5183900A (en) * 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
US5892112A (en) * 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
AU2228292A (en) * 1991-06-14 1993-01-12 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor
JPH05125029A (ja) * 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
EP0639982A1 (en) * 1992-05-01 1995-03-01 British Biotech Pharmaceuticals Limited Use of mmp inhibitors
US5318964A (en) * 1992-06-11 1994-06-07 Hoffmann-La Roche Inc. Hydroxamic derivatives and pharmaceutical compositions
US5326760A (en) * 1992-06-29 1994-07-05 Glaxo, Inc. Aminobutanoic acid compounds having metalloprotease inhibiting properties
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
WO1994025434A1 (en) * 1993-04-27 1994-11-10 Celltech Limited Peptidyl derivatives as metalloproteinase inhibitors
EP0712390B1 (en) * 1993-08-02 1998-12-09 Celltech Therapeutics Limited Succinamide derivatives, processes for their preparation and their use as gelatinase and collagenase inhibitors
US5545735A (en) * 1993-10-04 1996-08-13 Merck & Co., Inc. Benzo-Fused Lactams promote release of growth hormone
US5470834A (en) * 1993-10-06 1995-11-28 Florida State University Sulfoximine and suldodiimine matrix metalloproteinase inhibitors
US5403952A (en) * 1993-10-08 1995-04-04 Merck & Co., Inc. Substituted cyclic derivatives as novel antidegenerative agents
GB9323165D0 (en) * 1993-11-10 1994-01-05 Chiros Ltd Compounds
CN1049651C (zh) * 1994-01-20 2000-02-23 英国生物技术药物有限公司 金属蛋白酶抑制剂
GB9401129D0 (en) * 1994-01-21 1994-03-16 British Bio Technology Hydroxamic acid derivatives as metalloproteinase inhibitors
EP0905126B1 (en) * 1994-01-22 2002-12-04 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5514716A (en) * 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
US5665753A (en) * 1994-03-03 1997-09-09 Smithkline Beecham Corporation Cytokine inhibiting imidazole substituted hydroxamic acid derivatives
GB9405076D0 (en) * 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors
DE4411311A1 (de) * 1994-03-31 1995-10-05 Basf Ag Verfahren zur Herstellung von lagerstabilen wäßrigen Lösungen von Vinylamin-Einheiten enthaltenden Polymerisaten
GB9501737D0 (en) * 1994-04-25 1995-03-22 Hoffmann La Roche Hydroxamic acid derivatives
US6028110A (en) * 1994-05-28 2000-02-22 British Biotech Pharmaceuticals Ltd. Succinyl hydroxamic acid, N-formyl-N-hydroxy amino carboxylic acid and succinic acid amide derivatives as metalloprotease inhibitors
GB9411088D0 (en) * 1994-06-03 1994-07-27 Hoffmann La Roche Hydroxylamine derivatives
CN1151157A (zh) * 1994-06-22 1997-06-04 英国生物技术药物有限公司 金属蛋白酶抑制剂
GB9416897D0 (en) * 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
HRP950558A2 (en) * 1994-11-15 1997-12-31 Scott M. Wilhelm Substituted 4-biarylbutric or biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors
US5919940A (en) * 1995-01-20 1999-07-06 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5886022A (en) * 1995-06-05 1999-03-23 Bayer Corporation Substituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitors
US6124333A (en) * 1995-06-22 2000-09-26 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
TW453995B (en) * 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
ES2284180T3 (es) * 1996-01-23 2007-11-01 SHIONOGI & CO., LTD. Derivados de aminoacidos sulfonados e inhibidores de metaloproteinasas que contienen los mismos.
WO1998009940A1 (en) * 1996-09-04 1998-03-12 Warner-Lambert Company Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
BR9810841A (pt) * 1997-07-31 2001-07-10 Procter & Gamble Inibidores de metaloprotease alicìclicos
US6225311B1 (en) * 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors

Also Published As

Publication number Publication date
WO2001070682A3 (en) 2002-01-31
NO20024482L (no) 2002-09-19
JP2003528078A (ja) 2003-09-24
AR030196A1 (es) 2003-08-13
MXPA02009310A (es) 2003-03-12
EP1265887A2 (en) 2002-12-18
BR0109354A (pt) 2003-04-15
ZA200206299B (en) 2003-02-19
SK13362002A3 (sk) 2003-04-01
MA25783A1 (fr) 2003-07-01
PL357275A1 (en) 2004-07-26
KR20030005229A (ko) 2003-01-17
IL151126A0 (en) 2003-04-10
CN1418209A (zh) 2003-05-14
HUP0300998A3 (en) 2004-10-28
US20030162778A1 (en) 2003-08-28
CA2403778A1 (en) 2001-09-27
CZ20023179A3 (cs) 2003-02-12
WO2001070682A2 (en) 2001-09-27
AU2001249269A1 (en) 2001-10-03
PE20011187A1 (es) 2001-12-12
RU2002128003A (ru) 2004-02-27
NO20024482D0 (no) 2002-09-19

Similar Documents

Publication Publication Date Title
HUP0300262A2 (hu) Heterociklusos oldalláncot tartalmazó metalloproteáz inhibitorok
PT1263730E (pt) Derivados amina para o tratamento de apoptose
HUP9903916A2 (hu) Foszfinsavamidok és ezeket tartalmazó gyógyszerkészítmények
DK1259485T3 (da) Benzamider og beslægtede inhibitorer for faktor Xa
TNSN03045A1 (en) QUINAZOLINES AS MMP-13 INHIBITORS
UY27357A1 (es) Nuevos agentes antidiabéticos .
HUP0203575A2 (hu) Th2 differenciálódás inhibitorokat tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE273305T1 (de) Thrombin-inhibitoren
DK1065204T3 (da) Bicykliske carbonyl-indolforbindelser som anti-inflammatoriske/analgesiske midler og som COX-2-inhibitorer
BR9909620A (pt) Inibidores de metaloproteases de hidroxamato de pirrolidina substituìdo
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
HUP0300235A2 (hu) Heterociklikus oldalláncot tartalmazó, N-szubsztituált metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
BR0315820A (pt) Inibidores de integrase de hiv, composições farmacêuticas e métodos para a sua utilização
HUP0201284A2 (hu) Hatóanyagként kinazolindionszármazék kimáz inhibitort tartalmazó gyógyászati készítmények fibrózis megelőzésére vagy kezelésére
ATE440838T1 (de) Pharmazeutisch aktive sulfonylaminosäurederivate
ATE253359T1 (de) Antithrombotische mittel
DK0952159T3 (da) Anvendelse af phenylhydrazonderivater som antiinflammatoriske eller analgetiske midler
NO920438D0 (no) N-(aryloksyalkyl)heteroaryl-8-azabicyklo(3.2.1.)oktaner, mellomprodukter og en fremgangsmaate for fremstilling deravsamt anvendelse som medikamenter
NO983444L (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
BR9807330A (pt) Agentes inibidores do progresso de pterìgio e recorrência pós-operatória do mesmo
HUP0300998A2 (hu) Karbociklusos oldalláncot tartalmazó metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0203118A2 (hu) Béta-diszubsztituált metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ITMI922742A1 (it) Composti ad attivita' terapeutica utili per il trattamento di malattie connesse ad una carenza di glutatione, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
ATE286395T1 (de) Antithrombotische mittel
ATE56967T1 (de) Amidderivate.